PET500 will target men who suffer situational or occasional Premature Ejaculation (PE) for which there is currently no licensed product available within the EU or US. We believe that men who experience this mild to moderate form of PE will respond well to a rapidly acting compound. This would allow men greater control over their sexual performance and enjoyment, increasing sexual satisfaction for them and their sexual partner.
PE is a complex condition with many psychological factors, it is therefore essential that, as a non-prescription product, it is developed to meet both the expectations of the PE sufferer as well as those of their sexual partner.
PET500 utilises Futura's proprietary skin delivery technology DermaSys® and will contain a well characterised mild topical anaesthetic compound.
Futura has undertaken qualitative market research in order to help design a product to meet this unmet clinical need. Following formulation work, PET 500 is now ready to enter into clinical studies. We expect to start a Phase I study in Q2 2008 to evaluate the product’s characteristics.
Commercial status: PET500 is not currently partnered.
PET500 will utilise our skin delivery technology
